During the last session, CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares were 1,147,258, with the beta value of the company hitting 2.24. At the end of the trading day, the stock’s price was $131.88, reflecting an intraday loss of -2.7% or -$3.66. The 52-week high for the CRSP share is $220.2, that puts it down -66.97% from that peak though still a striking +70.24% gain since the share price plummeted to a 52-week low of $39.25. The company’s market capitalization is $9.99 Billion, and the average intraday trading volume over the past 10 days was 1.5 Million shares, and the average trade volume was 2.34 Million shares over the past three months.
CRISPR Therapeutics AG (CRSP) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.2. CRSP has a Sell rating from 2 analyst(s) out of 21 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 13 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $1.51.
CRISPR Therapeutics AG (CRSP) registered a -2.7% downside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.15% in intraday trading to $137.5 this Monday, Apr 26, hitting a weekly high. The stock’s 5-day price performance is 4.76%, and it has moved by 19.11% in 30 days. Based on these gigs, the overall price performance for the year is -13.87%. The short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) is 4.25 Million shares and it means that shorts have 1.82 day(s) to cover.
The consensus price target of analysts on Wall Street is $154.17, which implies an increase of 16.9% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $45 and $220 respectively. As a result, CRSP is trading at a discount of 66.82% off the target high and -65.88% off the low.
CRISPR Therapeutics AG (CRSP) projections and forecasts
Statistics show that CRISPR Therapeutics AG has outperformed its competitors in share price, compared to the industry in which it operates. CRISPR Therapeutics AG (CRSP) shares have gone up +34.41% during the last six months, with a year-to-date growth rate more than the industry average at 51.42% against 8%. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 216.2% this quarter and then jump 18.2% in the quarter after that. In the rating firms’ projections, revenue will increase 43564.8% compared to the previous financial year.
Revenue for the current quarter is expected to be $282.22 Million as predicted by 16 analyst(s). Meanwhile, a consensus of 16 analyst(s) estimates revenue growth to $57.31 Million by the end of September 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $18.12 Million and $148Million respectively. In this case, analysts expect current quarter sales to grow by 1457.5% and then jump by 38623% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -52.5%. While earnings are projected to return -550.5% in 2021, the next five years will return 0% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Biggest Investors
CRISPR Therapeutics AG insiders own 12.93% of total outstanding shares while institutional holders control 70.33%, with the float percentage being 80.77%. ARK Investment Management, LLC is the largest shareholder of the company, while 530 institutions own stock in it. As of Dec 30, 2020, the company held over 10.41 Million shares (or 13.81% of all shares), a total value of $1.59 Billion in shares.
The next largest institutional holding, with 7.43 Million shares, is of Capital International Investors’s that is approximately 9.85% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $1.14 Billion.
Also, the Mutual Funds coming in first place with the largest holdings of CRISPR Therapeutics AG (CRSP) shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. Data provided on Mar 30, 2021 indicates that ARK ETF Tr-ARK Innovation ETF owns about 5,314,530 shares. This amounts to just over 7.05 percent of the company’s overall shares, with a $647.58 Million market value. The same data shows that the other fund manager holds slightly less at 2.1 Million, or about 2.78% of the stock, which is worth about $255.64 Million.